ArticleInternal and emergency medicine2026
Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease should be treated with sodium-glucose cotrasporter 2 (SGLT-2) inhibitors, alone or in combination with renin-angiotensin system (RAS) inhibitors, in order to reduce their cardiovascular and renal risk. We conducted a multicenter, retrospective, observational cohort study using data from the Italian REPOSI registry, including 1372 patients with diabetes aged ≥ 65 years hospitalized with cardiovascular diseases (heart failure or ischemic heart disease), chronic kidney disease or cardiorenal disease, between 2008 and 2024, with the purpose of analyzing the prescription in these patients of SGLT-2 inhibitors, alone or in combination with RAS-inhibitors, before and after the implementation of Note AIFA 100 in 2022. The prescription of SGLT-2 inhibitors alone and also their combination with RAS-inhibitors is scarce in patients with diabetes and cardiovascular, renal and cardiorenal comorbidities attending internal medicine and geriatric Italian wards, across all eGFR categories, with never users ranging from 96.9% to 98.9%. The regulatory implementation of "Nota AIFA 100" only modestly improved the prescription of SGLT-2 inhibitors in these elderly patients, the improvement being about 14% among never users. The scarce utilization of SGLT-2 inhibitors and their combination with RAS inhibitors is still of clinical concern, owing to the maximization of cardiorenal protection that stems from these drugs in patients with diabetes. The reclassification of SGLT-2 inhibitors in the group of products that can be reimbursed in pharmacies, adopted by AIFA in 2025, is expected to produce greater adherence to these important medications.
Indexed as
Identifiers
42642609What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.